Advertisement
Canada markets open in 7 hours 32 minutes
  • S&P/TSX

    21,581.35
    +64.45 (+0.30%)
     
  • S&P 500

    5,473.17
    -13.86 (-0.25%)
     
  • DOW

    39,134.76
    +299.90 (+0.77%)
     
  • CAD/USD

    0.7312
    +0.0006 (+0.08%)
     
  • CRUDE OIL

    82.34
    +0.17 (+0.21%)
     
  • Bitcoin CAD

    88,383.55
    -1,215.76 (-1.36%)
     
  • CMC Crypto 200

    1,352.99
    -29.68 (-2.15%)
     
  • GOLD FUTURES

    2,377.20
    +8.20 (+0.35%)
     
  • RUSSELL 2000

    2,017.39
    -7.84 (-0.39%)
     
  • 10-Yr Bond

    4.2540
    -4.2170 (-49.78%)
     
  • NASDAQ futures

    19,800.00
    +36.75 (+0.19%)
     
  • VOLATILITY

    13.28
    +0.80 (+6.41%)
     
  • FTSE

    8,272.46
    +67.35 (+0.82%)
     
  • NIKKEI 225

    38,603.00
    -30.02 (-0.08%)
     
  • CAD/EUR

    0.6820
    -0.0001 (-0.01%)
     

Biogen in up to $1.8 billion deal as rare diseases take center stage

Illustration shows Biogen logo

(Reuters) -Biogen said on Wednesday it had agreed to buy privately held Human Immunology Biosciences for up to $1.8 billion, bulking up on rare disease medicines as its older multiple sclerosis drugs face tepid demand due to rising competition.

Human Immunology's (HI-Bio) felzartamab has completed mid-stage studies for a type of kidney disease called primary membranous nephropathy, and in patients with a disease where the immune system makes antibodies that damage their transplanted organ.

The San Francisco-based company is also testing the therapy in patients with another chronic kidney disease known as IgA nephropathy. The therapy developer plans to conduct late-stage trials.

Since Christopher Viehbacher took the helm in late 2022, Biogen has acquired rare disease drugmaker Reata for $6.5 billion, abandoned its controversial Alzheimer's disease drug Aduhelm and cut jobs.

ADVERTISEMENT

The company is now counting on newer medicines such as a second approved Alzheimer's drug Leqembi, developed with Japanese partner Eisai, as well as Reata's Skyclarys to help drive growth.

The deal consists of $1.15 billion in upfront and up to $650 million in potential payments if felzartamab achieves certain development milestones.

The deal is expected to close in the third quarter, the companies said on Wednesday. HI-Bio is backed by investors such as biotech-focused ARCH Venture Partners and Monograph Capital.

(Reporting by Manas Mishra and Sriparna Roy in Bengaluru; Editing by Sriraj Kalluvila)